GT200800038A - Metodo para prevenir la contracepción hormonal contra demanda - Google Patents

Metodo para prevenir la contracepción hormonal contra demanda

Info

Publication number
GT200800038A
GT200800038A GT200800038A GT200800038A GT200800038A GT 200800038 A GT200800038 A GT 200800038A GT 200800038 A GT200800038 A GT 200800038A GT 200800038 A GT200800038 A GT 200800038A GT 200800038 A GT200800038 A GT 200800038A
Authority
GT
Guatemala
Prior art keywords
hormonal contraception
against demand
prevent
demand
prevent hormonal
Prior art date
Application number
GT200800038A
Other languages
English (en)
Spanish (es)
Inventor
Karin Schmidt-Gollwitzer
Guenter Stock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200800038A publication Critical patent/GT200800038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT200800038A 2005-10-19 2008-04-18 Metodo para prevenir la contracepción hormonal contra demanda GT200800038A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005050729A DE102005050729A1 (de) 2005-10-19 2005-10-19 Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption

Publications (1)

Publication Number Publication Date
GT200800038A true GT200800038A (es) 2009-04-01

Family

ID=37762565

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800038A GT200800038A (es) 2005-10-19 2008-04-18 Metodo para prevenir la contracepción hormonal contra demanda

Country Status (13)

Country Link
US (3) US20080311180A1 (enExample)
EP (1) EP1937275A1 (enExample)
JP (2) JP2009512658A (enExample)
KR (1) KR20080056774A (enExample)
CN (1) CN101340915A (enExample)
BR (1) BRPI0617683A2 (enExample)
CA (1) CA2626567C (enExample)
CR (1) CR9908A (enExample)
DE (1) DE102005050729A1 (enExample)
EC (1) ECSP088390A (enExample)
GT (1) GT200800038A (enExample)
HN (1) HN2008000621A (enExample)
WO (1) WO2007045513A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
WO2010119029A1 (en) * 2009-04-14 2010-10-21 Laboratoire Hra-Pharma Method for on-demand contraception
US20120129825A1 (en) * 2009-04-14 2012-05-24 Andre Ulmann Method for on-demand contraception using levonorgestrel or norgestrel
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
SG11201503275RA (en) 2012-11-22 2015-06-29 Bayer Pharma AG Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105451737B (zh) 2013-05-23 2018-04-10 拜耳医药股份有限公司 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
NZ295365A (en) * 1994-10-24 1999-07-29 Schering Ag Competitive progesterone antagonists for regulating female fertility as required
EP1605949A2 (en) * 1999-08-31 2005-12-21 Schering Aktiengesellschaft Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
AU2003245252A1 (en) * 2002-04-30 2003-11-17 Fmc Corporation Carrageenan based antimicrobial compositions
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
CN1913878B (zh) * 2003-12-12 2010-05-26 拜耳先灵医药股份有限公司 无需渗透促进剂的激素透皮传递

Also Published As

Publication number Publication date
CR9908A (es) 2008-05-21
CN101340915A (zh) 2009-01-07
DE102005050729A1 (de) 2007-04-26
WO2007045513A1 (de) 2007-04-26
US20130089574A1 (en) 2013-04-11
JP2014001239A (ja) 2014-01-09
JP2009512658A (ja) 2009-03-26
CA2626567A1 (en) 2007-04-26
ECSP088390A (es) 2008-05-30
KR20080056774A (ko) 2008-06-23
BRPI0617683A2 (pt) 2011-08-02
EP1937275A1 (de) 2008-07-02
US20080311180A1 (en) 2008-12-18
US20070111976A1 (en) 2007-05-17
HN2008000621A (es) 2011-07-22
CA2626567C (en) 2013-12-03

Similar Documents

Publication Publication Date Title
ECSP088390A (es) Método para la anticoncepción hormonal preventiva bajo demanda
ES2540751T3 (es) Composición para mejorar la función sexual masculina que contiene extracto de baya de ginseng
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
ECSP10010295A (es) Formulacion de anticuerpo
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
IL201479A (en) Use of tapentadol for the preparation of pain medication
CR10732A (es) Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina
AR048833A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
DOP2011000354A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
CL2010001366A1 (es) Composicion farmaceutica de liberacion controlada que comprende topiramato, celulosa microcristalina y metilcelulosa; preparado farmaceutico que la comprende, util para tratar la obesidad, diabetes o una afeccion relacionada.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
JOP20200260B1 (ar) مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
BR112017028048A2 (pt) drospirenona como o único ingrediente contraceptivo para uso
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
CL2015001368A1 (es) Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta".
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
PE20160239A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
CU20080067A7 (es) Método para la anticoncepción hormonal preventiva bajo demanda